{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-042420","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.851365+00:00","generated_at":"2026-06-11T11:34:52.176208+00:00","sec_items":["2.02","9.01","8.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spruce Biosciences Q2 net loss $12.8M; reports positive PCOS interim data","bullets":["Net loss of $12.8M for Q2 2023 vs $11.9M for Q2 2022; six-month loss $25.6M.","Cash, equivalents and investments of $120.5M; expected to fund operations into H1 2025.","Collaboration revenue $2.2M from Kaken Pharmaceutical upfront payment recognition.","Interim Phase 2 PCOS data (20 patients) suggests DHEAS reduction with tildacerfont; no serious AEs.","CAHmelia-203 enrollment >75%; CAHmelia-204 nearing 75%; CAHptain cohort 3 screening underway."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-042420","json":"https://secwatch.observer/filing/0000950170-23-042420.json","markdown":"https://secwatch.observer/filing/0000950170-23-042420.md","text":"https://secwatch.observer/filing/0000950170-23-042420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023042420/0000950170-23-042420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023042420/sprb-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:34:52.176208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71807bdd65cb6d4094d19a6304cc1000fdde9476","claim":"SPRUCE BIOSCIENCES, INC. reported second quarter ended June 30, 2023 results: revenue $2.2 million.","evidence_excerpt":"to fund operating and capital expenditures into the first half of 2025. • Collaboration Revenue: Collaboration revenue for the three and six months ended June 30, 2023 were $2.2 million and $4.1 million, respectively, compared to nil for the same periods in 2022. The increase in collaboration revenue reflects the partial recognition of the $15.0 million upfront","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023042420/0000950170-23-042420-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$2.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}